Partner's bispecific Bizengri nabs FDA national priority nod in rare bile duct cancer

With the program’s seventh approval in the books, the FDA is illustrating just how speedy it can be with drug reviews that fall under its U.S. national priority pilot.

Nội dung đang được cập nhật.